Oramed Pharmaceuticals (ORMP) Gains from Investment Securities (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has 4 years of Gains from Investment Securities data on file, last reported at $3.3 million in Q1 2025.

• Quarterly Gains from Investment Securities rose 189.33% year-over-year to $3.3 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $14.5 million (up 172.27% YoY) and the FY2025 annual result came in at -$86.1 million, down 1261.42% from the prior year.
• Gains from Investment Securities slipped to $3.3 million in Q1 2025, from $7.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $16.6 million in Q3 2024 to a low of -$16.2 million in Q4 2023.
• A 4-year average of -$536200.0 and a median of $102000.0 in 2022 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities plunged 6122.68% — and 2024, when it jumped 2535.77%.
• Tracing ORMP's Gains from Investment Securities over 4 years: stood at $269000.0 in 2022, then sank by 6122.68% to -$16.2 million in 2023, then soared by 146.62% to $7.6 million in 2024, then sank by 55.67% to $3.3 million in 2025.
• The last three Gains from Investment Securities figures came in at $3.3 million (Q1 2025), $7.6 million (Q4 2024), and $16.6 million (Q3 2024), per Business Quant data.